UK markets close in 1 hour 11 minutes

Crescita Therapeutics Inc. (CRRTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.32000.0000 (0.00%)
As of 02:14PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 6.14M
Enterprise value 198.62k
Trailing P/E 23.38
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.51
Price/book (mrq)0.45
Enterprise value/revenue 0.01
Enterprise value/EBITDA 3.26

Trading information

Stock price history

Beta (5Y monthly) 1.65
52-week change 3-35.56%
S&P500 52-week change 324.19%
52-week high 30.5500
52-week low 30.2500
50-day moving average 30.3242
200-day moving average 30.3853

Share statistics

Avg vol (3-month) 325
Avg vol (10-day) 3N/A
Shares outstanding 519.54M
Implied shares outstanding 619.67M
Float 817.15M
% held by insiders 110.35%
% held by institutions 10.00%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CAD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -11.33%
Operating margin (ttm)-2.39%

Management effectiveness

Return on assets (ttm)-4.61%
Return on equity (ttm)-9.95%

Income statement

Revenue (ttm)17.52M
Revenue per share (ttm)0.87
Quarterly revenue growth (yoy)-21.60%
Gross profit (ttm)N/A
EBITDA -857k
Net income avi to common (ttm)-1.99M
Diluted EPS (ttm)-0.0700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)9.39M
Total cash per share (mrq)0.48
Total debt (mrq)1.25M
Total debt/equity (mrq)6.66%
Current ratio (mrq)3.80
Book value per share (mrq)0.94

Cash flow statement

Operating cash flow (ttm)2.08M
Levered free cash flow (ttm)2.06M